Login to Your Account

Clinic Roundup

Wednesday, December 19, 2012

• Orexigen Therapeutics Inc., of San Diego, provided an update on its cardiovascular outcomes trial for obesity candidate Contrave (naltrexone SR/buproprion).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription